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Apelin is a recently discovered peptide, identified as an 
endogenous ligand of receptor APJ. Apelin and receptor APJ 
are expressed in a wide variety of tissues including heart, 
brain, kidneys and lungs. Their interaction may have relevant 
pathophysiologic effects in those tissues. In fact, the last 
decade has been rich in illustrating the possible roles played by 
apelin in human physiology, namely as a regulating peptide of 
cardiovascular, hypothalamus-hypophysis, gastrointestinal, and 
immune systems. The possible involvement of apelin in the 
pathogenesis of high prevalence conditions and comorbidities 
– such as hypertension, heart failure, and Diabetes Mellitus 
Type 2 (T2DM) – rank it as a likely therapeutic target to be 
investigated in the future. The present paper is an overview 
of apelin physiologic effects and presents the possible role 
played by this peptide in the pathogenesis of a number of 
conditions as well as the therapeutic implications that might, 
therefore, be investigated.
Introduction
In 1993, O’Dowd et al1 identified a gene with closest 
identity to the angiotensin II type 1 receptor (AT-1). This 
receptor – APJ – was kept “orphan” until 1998, when Tatemoto 
et al2 identified a selective endogenous ligand, named apelin. 
The first studies have demonstrated that apelin and its receptor 
are expressed practically ubiquitously, thus acquiring special 
status at organs such as heart, brain, kidneys, and lungs3-6.
The apelinergic system distribution over such variety of 
tissues has suggested it might play relevant roles in human 
physiology. Indeed, apelin is involved in the regulation of 
cardiovascular, gastrointestinal, and immune functions, as well 
as in bone physiology, fluid homeostasis and cardiovascular 
system embryonal development7-9. Recently, the apelinergic 
system has been demonstrated to be involved in the 
pathogenesis of a number of high prevalence conditions – such 
as hypertension, heart failure (HF), obesity, glucose intolerance 
and diabetes mellitus type 2 (T2DM), as well as HIV infections, 
diabetes insipidus, gastric ulcer and osteoporosis7-9. Therefore, 
it is a growing consensus that the modulation of the apelin/APJ 
binomial may be a therapeutic target to be investigated in 
the future10,11.
With that in mind, the purpose of the present paper is 
to review the apelinergic system and provide an overview 
of its physiologic and pathologic involvement, so that a 
better understanding of the apelin/APJ binomial may lead 
to new investigations as well as to possible future clinical 
applications.
APJ receptor
In 1993, O’Dowd et al1 characterized a 700 base pair 
fragment by using polymerase chain reaction (PCR). A 
detailed analysis revealed a number of similarities with 
transmembrane domains gene sequences of GPCRs (G 
protein-coupled membrane receptors). The codified protein 
had 380 aminoacids and was named APJ. 
High homology between APJ receptor and AT-1 receptor 
was soon identified: 115 aminoacids (AA) (30%) of the total 
sequence and 86 AA (54%) in transmembrane regions1, as well 
as high similarity in the tissue expression of both receptors3. 
However, apelin, an endogenous ligand of the APJ receptor, 
does not bind to AT-1 receptor12, nor does angiotensin II 
(AngII) binds to APJ1,2.
Although predominantly located in the membrane, APJ 
Receptor was also found in the nucleus of cerebellum and 
human hypothalamus cells – a nuclear localization signal 
was identified in the third intracellular loop13. These data 
suggest that this receptor may play a role in gene transcription 
regulation, as previously shown for AngII10 – an aspect that 
should be a topic for investigation in the future. 
After studying APJ receptor distribution in rats, mice, and 
humans, the conclusion was that it is abundantly expressed 
in the central nervous system (CNS), as well as in a number 
of peripheral tissues, especially in lung and heart1,3-5,14. A 
number of studies have shown that in the cardiovascular 
system the APJ receptor is found in the endothelial cells of 
small intramyocardial, renal, pulmonary and adrenal vessels, 
in coronary arteries, in endocardial endothelium cells, and 
in vascular smooth muscle cells5. Interestingly enough, APJ 
immunoreactivity follows a transversally estriated pattern in 
cardiomyocytes, thus indicating the co-localization of receptor 
with T-tubules5.
Apelinergic peptides
APJ receptor was kept orphan until 1998, when Tatemoto 
et al2 isolated a 36-AA peptide from bovine stomach extracts, 
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which they named apelin. The peptide induced extracellular 
acidification and inhibited cAMP formation in a cell line of 
Chinese hamster ovaries that expressed the APJ receptor. The 
localization of the pre-proapelin codifying gene - a 77 AA 
pre-peptide – in humans is Xq25-26.1, with 1,726 base pairs 
that include 3 exons. Curiously enough, high homology was 
shown between the different species in pre-proapelin protein 
sequence, namely in the 23 AA in terminal C12. Indeed, 65-77 
C-terminal fragment of apelinergic peptides is key to bind to 
APJ receptor and to its biological activity, whereas N-terminal 
plays a key role in modulating ligand-receptor interaction15.
The first studies on apelin identified different isoforms which 
are thought to exist in vivo: apelin-36 (apelin42-77), apelin-17 
(apelin61-77), apelin-13 (apelin65-77) and apelin-13 in its 
pyroglutaminated form [(Pyr1)apelin-13], which means to say, 
with N-terminal glutamate residue2. While shorter isoforms 
seem to be more powerful in their cardiovascular action, 
apelin-36 is more efficient in blocking HIV infection in APJ-
positive cells. It is currently thought that Apelin-36 acts as a 
precursor, with limited biological activity, up to the moment 
it is under proteolysis and post-translational changes, to then 
produce biologically more active peptides, predominantly 
(Pyr1)Apelin-13, whose pyroglutamination preserves biological 
function and prevents enzyme degradation8. Lee et al16 have 
described a possible APJ receptor antagonist: by substituting 
terminal C phenylalanine in Apelin-13 with alanine residue, a 
peptide is created. In a dose-dependent mode, that peptide 
annihilates the hypotensive action of IV Apelin-13 in rats. 
The early studies that characterized apelin tissue distribution 
were conducted in rats’ tissues, and evidenced the presence 
of its pre-propeptide in a wide variety of tissues3,4,6,12,17. In 
humans, pre-proapelin RNAm is abundant in the CNS and in 
the placenta, as well as in more moderate volume in kidneys, 
heart, lungs and mammary gland. It should be pointed 
out that apelin is biologically active in the myocardium, in 
cardiac endothelium, and in the endothelium of large vessels 
and small veins and arteries7. In endothelial cells, apelin is 
not found in Weibel-Palade bodies, vesicles resulting from 
induced endothelial peptide secretion, thus suggesting apelin 
consitutive release5.
An immunoenzyme assay estimated the concentration 
of circulating apelin in humans to be between 3 and 4 
ng/mL18. This is a low concentration if compared to that of 
other circulating hormones. However, it is comparable to 
endothelium-derived vasoactive mediators, which suggests 
endothelial release of apelin. 
It is currently thought that carboxypeptidase ACE2 
(Angiotensin Converting Enzyme 2) plays the role of apelin 
degradation through highly efficacious cleavage of the 
terminal C phenylalanine from the apelinergic peptides19. 
Such correlation therefore suggests the high relevance of 
apelin in cardiovascular regulation since ACE2 is involved in 
the renin-angiotensin-aldosterone system8. Indeed, ACE2 is 
also involved in the degradation of Ang II to angiotensin 1-7, 
which, opposedly to Ang II, seems to play relevant functions 
in cardiac and renal protection20. Therefore, the induction 
of that enzyme may, in the future, be a therapeutic target in 
major cardiovascular pathologies. 
Interaction apelin/APJ
One of the major transduction pathways for apelin signal 
depends on the interaction with a Gi-protein coupled to the APJ 
receptor, independently of Ras protein; although dependent 
on Protein Kinase C (PKC)7. Indeed, if PKC, phospholipase C 
(PLC), the Na+-H+ (NHE) exchanger and  the Na+-Ca2+(NCX) 
exchanger are inhibited, apelin effects will be significantly 
reduced, namely in regard to its positive inotropic effect21. 
It should be pointed out that PKC activation results in NHE 
phosphorylation, which promotes inner cell alkalinization and 
sensitization of myofilaments to Ca2+, as well as NCX activation, 
whose action is then reversed to promote Ca2+ entry into the cell 
(Figure 1). Hashimoto et al22 have recently demonstrated that 
apelin induces phosphorylation of myosin light chain in vascular 
smooth muscle cells, which is of major relevance in initiating 
smooth muscle contraction. The inhibition of PKC, NHE and 
NCX is translated into a significant reduction of that effect.
In addition to adenyl cyclase inhibition pathway, apelin 
activates ERKs (extracellular regulated kinases) pathways 
through a PTX (pertussis toxin) sensitive G protein, in a 
Figure 1 - Intracellular pathways responsible for positive inotropic effect of the apelin/APJ interaction. DAG - Diacylglycerol; Gi - Inhibitory G protein; IP3 - Inositol 
Triphosphate; NCX - Na+/Ca2+ Exchanger; NHE - Na+/H+ Exchanger; PKC - Protein Kinase C; PLC - Phospholipase C; SR - Sarcoplasmatic Reticulum.
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PKC-dependent process23. PI3K-p70S6K endothelial cells 
proliferation control is also activated by apelin through 
two mechanisms: one is ERK-dependent and the other is 
PI3K-dependent24. It is important to point out that PI3K/Akt 
seems to be responsible for the phosphorilation and resulting 
activation of endothelial nitric oxide (eNOS) synthase, which 
is indispensable for most of apelin vasoactive effects25.
Apelin/APJ: the role played in human 
physiology and pathology and potential 
therapeutic applications
Cardiovascular development and homeostasis
Apelin and its receptor are expressed in embryonal and 
adult tissues. As a result, they perform a wide action spectrum, 
starting at very early stages of cardiovascular development 
which goes on to adult life. Their contribution is increasingly 
evident in a number of pathophysiologic processes. 
The high expression of APJ receptor in the endothelium of 
embryonal vessels and in the tunica intima of retinal vessels 
has already been demonstrated14, as well as increased and 
reduced expression of that receptor in the formation and 
stabilization of retinal vessels, respectively26. 
Those data give stronger support to the idea that apelin 
plays a major role in endothelial cell proliferation – whether 
at embryonal development and physiologic states, or at 
pathological states (for instance, malignant neoplasms 
and diabetic retinopathy). Therefore, possible therapeutic 
applications may be envisaged for the future, such as the use 
of agonists to promote therapeutic angiogenesis (for instance, 
for ischemic conditions), as well as angiogenic antagonists, as a 
strategy to control tumoral growth and diabetic retinopathy.
Early studies on apelin and APJ receptor tissue distribution 
pointed towards high expression of their RNAm in the 
heart and in blood vessels of rats and humans4,6,14,17,18. APJ 
expression was especially high in rat’s heart15, while apelin 
was abundantly expressed in human endothelial cells of 
large conduction vessels3. More recently, APJ receptor RNAm 
was detected in the tunica media of large vessels27, as well 
as immunoreactivity to apelin in endothelial cells of small 
resistance vessels28. 
In 2000, Lee et al12 demonstrated for the first time that 
after IV infusion of apelin-13 in anesthetized rats, systolic 
and diastolic pressures reported temporary decrease 
(approximately 10mmHg). In the follow-up, another group 
of investigators demonstrated that the hypotensive effect was 
inversely correlated to apelin isoform molecular weight. That 
effect was absent after the administration of an NO synthase 
inhibitor (NOS)25, which suggests that apelin vasoactive effects 
occur through an NO-dependent mechanism. Indeed, apelin 
causes endothelium-dependent vasodilation through the Akt 
activation that phosphorylates eNOS and promotes NO release 
as well as increased GMPc levels25. However, it may trigger 
a vasoconstrictive response if encountering a dysfunctional 
endothelium, in which case it will act on the vascular smooth 
muscle cells, which also express APJ receptor27 (Figure 2). 
In reference to cardiac effects, Szokodi et al21 have 
demonstrated that in intact rat heart preparations, apelin-
16 had a positive inotropic effect, increasing contractility 
with an approximately 30 pM EC50, and maximum effect of 
approximately 70% response to isoprenalin (β-adrenergic 
agonist). In vivo experiments have confirmed those results 
through increased maximum pressure developed (Pmax) and 
intraventricular pressure increase velocity (dP/dtmax), both in 
normal rats as in heart failure rats29. Hemodynamic studies 
in mice have demonstrated that the administration of apelin 
Figure 2 - Intracellular pathways responsible for the vasomotor effects in the apelin/APJ interaction in the absence and in the presence of endothelial dysfunction. 
DAG - Diacylglycerol; eNOS - Endothelial Nitric Oxide Synthase; Gi - Inhibitory G protein; sGC - Soluble Guanylate Cyclase; GTP - Guanosine triphosphate; cGMP 
- Cyclic Guanosine Monophosphate; IP3 - Inositol Triphosphate; L-Arg - L-Arginine; NCX - Na+/Ca2+ Exchanger; NHE - Na+/H+ Exchanger; NO - Nitric Oxide; PI3K 
- Phosphoinositide 3-kinase; PKC - Protein Kinase C; PLC - Phospholipase C.
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reduces left ventricle preload and afterload and chronically 
increases cardiac output, with no evidence of hypertrophy30. 
In addition to confirming the in vivo positive inotropic effect, 
a study in our group demonstrated apelin negative inotropic 
effect in isolated cardiac muscle, suggesting other cells may 
be required – in addition to myocardial cells – so that positive 
inotropic effect is revealed. We have also demonstrated that 
apelin does not perform any evident function on myocardial 
diastolic properties7. 
The apelin/APJ pair is intrinsically related to the AngII/AT-
1 pair in regulating the pathophysiology of cardiovascular 
function. Knock-out mice for APJ receptor present increased 
vasopressive response to Ang II. However, they present normal 
blood pressure levels31. In a major study by Iwanaga et al32 
involving HF rats (with reduced expression of apelin and APJ 
receptor), treatment with telmisartan – an antagonist of AT-1 
receptors – made apelin/APJ levels reverse back to normal, 
thus suggesting that the efficacy of AT1 receptors inhibition 
in HF may also result from restoring normal values of apelin, 
a powerful  positive inotropic endogenous  agent. Therefore, 
direct regulation of the apelin/APJ pair by AngII/AT1 is left as 
a suggestion.
The demonstration that physical exercise promotes 
increased apelin and APJ receptor expression in the 
myocardium of hypertensive rats, as well as the change from 
a pathologic, ethiologically hypertensive hypertrophy into a 
physiologic hypertrophy from exercising33 leads to the thought 
that physical exercise beneficial effect in reducing blood 
pressure levels in hypertensive individuals may be partially due 
to increased apelin/APJ expression at cardiovascular level.
In addition to its physiologic effects, apelin was also 
involved in the pathogenesis of HF. In the early studies, apelin 
circulating levels showed to be increased in recent onset HF 
patients, with progressive reduction accompanying worsening 
HF34. A wide-reaching populational study demonstrated 
that apelin serum concentration was reduced in patients 
presenting systolic HF due to left ventricular dysfunction35. 
Such decrease may result from the endothelial dysfunction 
associated to HF (thus affecting apelin production)34 or from 
the exhaustion of a possible compensatory mechanism for 
proper cardiac output maintenance carried out by apelinergic 
system in HF patients. In 2006, Dai et al36 demonstrated that 
apelin has a significant positive inotropic action on failing 
myocardium as a result of a transient increase of Ca2+. 
Recent studies have demonstrated that: 1) apelin therapy 
in rats with isoprenalin-induced lesions promotes the 
restoration of cardiac function, and is also cardioprotective, 
against lipidic peroxidation, for instance37; 2) apelin levels 
are reduced in coronary disease patients submitted to 
hemodialysis;  it is speculated that apelin may be involved in 
the physiopathology of cardiovascular disease secondary to 
chronic renal failure, and that it may be utilized in the future 
as a treatment approach for uremic cardiomyopathy38; 3) 
ventricular resinchronization therapy promotes a long-term 
increase of apelin plasma levels39, which may be associated 
to cardiac function improvement; 4) although it has been 
considered a possible marker for cardiac hypoxy (acute and 
chronic)40, 41 apelin circulating levels do not seem to be of help 
for the clinical evaluation and prognosis of acute or chronic HF 
patients35,42,43; 5) apelin may be utilized as a marker to assess 
the development of isolated atrial fibrillation44 as well as a 
diagnostic marker to distinguish the dyspnea from pulmonary 
causes from that of cardiovascular cause45.
In regard to the last aspect, Ellinor et al44 have demonstrated 
that apelin levels are reduced in patients with isolated atrial 
fibrillation, which suggests serum concentration of that peptide 
may be utilized as a risk index for the onset of that kind of 
arrhythmia in individuals with no manifestation. Interestingly, 
apelin-36 plasma levels are shown to be decreased in patients 
with pulmonary parenchyma chronic disease and preserved 
cardiac function. The determination of apelin-36 and proBNP 
(type B natriuretic peptide precursor) levels may, therefore, 
act as a new diagnostic method to distinguish dyspnea from 
pulmonary causes from that from cardiovascular cause45.
Hypothalamus-hypophysis axis and fluid homeostasis
As described earlier, APJ receptor and apelin are 
expressed in different areas at the CNS, particularly intensely 
in hypothalamic supra-optical (SON) and paraventricular 
(PVN) nuclei46,47. Given the expression pattern, it was soon 
suggested that the apelinergic system could be involved in the 
modulation of the hypothalamus-hypophysis axis activity as 
well as in fluid homeostasis.  
Indeed, as demonstrated earlier, apelin administration 
increases ACTH (adrenocorticotrophic hormone) and 
cortisone serum levels while decreasing prolactin, FSH 
(follicle stimulating hormone), and LH (luteinizing hormone) 
levels within 30 minutes after infusion. A recent study48 has 
demonstrated that apelin is typically localized in corticotropic 
cells, promoting autocrine/paracrine ACTH release, which 
points towards the presence of an  apelinergic system in adult 
rats’ hypophysis.
Although APJ receptor and apelin high expression in 
vasopressinergic neurons has suggested a relevant role played 
in fluid homeostasis, great discrepancy has been shown in 
corresponding results since the administration of apelin to rats 
was associated to both water consumption reduction46, and 
increase12,49. The absence of dipsic behavior effect in rats has 
also been described50. 
The unmasking of the association between apelin and 
body hydric homeostasis may allow the application of new 
therapeutic proposals associated to the apelin/APJ binomial for 
pathologies such as hypertension and diabetes insipidus.
Correlation with insulin, obesity and food intake
In 2005, Boucher et al51 demonstrated that apelin was a 
new endocrine adipokine produced at mature adipocytes 
of mice and humans. Additionally, relevant correlations 
with insulin and obesity have been established. Plasma and 
adipocyte apelin levels increase was evident in obese mice 
with hyperinsulinemia, as well as reduced apelin secretion by 
the adipocytes of insulin-dependent rats reporting low insulin 
levels and when fasting. That secretion was quickly replaced 
after food intake, thus leading to the conclusion that insulin 
increases apelin expression. This relevant correlation with 
insulin became more interesting when APJ receptor was shown 
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to have expression in pancreatic islets, and when apelin was 
shown to inhibit glucose-dependent insulin secretion through 
direct action on mice β- cells52.  
Interestingly, a positive correlation could be observed 
between apelin serum levels and body mass index (BMI)53. It was 
also observed that apelin serum levels are increased in diabetic 
or glucose intolerance54 patients, and that tumor necrosis factor-
α (TNF-α) increases apelin levels in human adipocytes55.
A most recent study on the pathophysiologic role played 
by apelin showed that its intraperitoneal administration in 
normal and obese mice for 14 days reduced body adiposity 
without affecting food intake, reduced insulin, leptin and 
triglycerides level, increased adiponectin levels, increased 
the expression of uncoupling proteins (UCP), and reduced 
respiratory quocient56.  
Apelin may also play a relevant role in regulating 
cardiovascular function in diabetes condition: diabetic mice 
treated with apelin reported increased vasodilating response 
to acetylcholine  through PI3K/Akt/eNOS pathway57.
All results seem to lead to the belief that apelin is a key regulator 
in a normal glucolipidic metabolism, also playing a possible role 
at pathologic scenarios such as obesity, insulin resistance and 
T2DM. Therefore, the use of apelin may be investigated as a 
potential therapeutic target for these pathologies.
As shown for fluid homeostasis, the role played by apelin in 
eating behavior is not yet well established, since data available 
are still scarce and contradictory56,58,59. Further studies are, 
therefore, required so that new conclusions on the role played 
by apelin in food intake can be reached.
Apelinergic system and new 
pathophysiologic implications
The apelinergic system actions described previously were 
the ones to draw closest attention on the part of medical 
community. However, there is an ongoing strong investigation 
task with the purpose of demonstrating new pathophysiologic 
implications of this newly found system.
Indeed, in regard to gastrointestinal function, the apelin/
APJ binomial seems to perform relevant functions in gastric 
acid and cholecystokinin secretion, as well as epithelial cell 
proliferation in stomach mucosa60, with possible involvement 
in the pathogenesis of peptic ulcer, ulcerous colitis61 and 
Crohn’s disease61. Apelin stimulates the proliferation of 
osteoblasts62,63 and inhibits apoptosis62,63. In the future, it 
may be used as therapeutic support for some bone diseases. 
Finally, the APJ receptor is a co-receptor for the entry of HIV 
in host’s cells18,64. Apelin was shown to inhibit the infection of 
CD4+ and APJ+ cells, with efficacy being higher in heavier 
isoforms65-67. 
Conclusion
The new roles played by the apelinergic system in human 
physiology and pathology are under continuing expansion. In 
fact, apelin is involved in the homeostasis regulation of major 
systems in our body, such as in the pathogenesis of a number 
of diseases, many of which accounting for extremely high 
levels of morbiditiy and mortality worldwide. There is a long 
way ahead, though. Further studies are required so that apelin 
and APJ receptor secrets can be revealed, thus expanding our 
knowledge on the functions performed by the apelinergic 
system in human physiology and pathology. Then, and only 
then, will the apelin/APJ system be properly considered as a 
future therapeutic target.
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